Table 7.

Influence of immunosuppressive treatments on the outcomes of patients with TA-proteinuria >0.75 g/d and persistent hematuria

Variable	All Patients, n=21	Treated, n=8	Nontreated, n=13	P Value
Baseline Scr, mg/dla	1.9±0.9	2±1.2	1.9±0.7	0.60
Baseline proteinuria, g/db	2.7 (1.2–4.4)	3.3 (1.3–5.6)	1.8 (1.2–3.3)	0.38
Baseline hematuria, RBC × hpfb	50 (28–100)	78 (33–100)	36 (14–87)	0.31
ESRD, no. (%)	11 (52)	4 (50)	7 (53.8)	0.86
50% Reduction in renal function, no. (%)	12 (57)	4 (50)	8 (61.5)	0.60
Rate of renal function decline, ml/min per 1.73 m2 per yra	−5.67±7.20	−5.75±8.19	−5.63±6.87	0.97
TA-P before/after IS treatment, g/db		2.9 (1.2–5.7)/1 (0.44–2.5)c
TA-H before/after IS treatment, RBC × hpfb		75 (20–100)/12 (4–20)d
Rate of renal function decline before/after IS treatment, ml/min per 1.73 m2 per yra		−10.2±12.7/−2±5.02e
IS treatments (%)
CS monotherapy		0 (0)
CS + MMF		5 (62)
CS + AZA		2 (25)
CS + CYC		1 (12)
Duration of CS treatment, moa		5.62±2.97
Cumulative dose of CS, mg/kgb		60 (44–66)

Scr, serum creatinine; TA-P, time-averaged proteinuria; IS, immunosuppressive treatment; TA-H, time-averaged hematuria; CS, corticosteroid; MMF, mycophenolate mofetil; AZA, azathioprine; CYC, cyclophosphamide.

^aMean±SD.

^bMedian (interquartile range).

^cP=0.01.

^dP=0.02.

^eP=0.12.